AU2010339907A1 - Compositions and methods for oral drug delivery - Google Patents

Compositions and methods for oral drug delivery Download PDF

Info

Publication number
AU2010339907A1
AU2010339907A1 AU2010339907A AU2010339907A AU2010339907A1 AU 2010339907 A1 AU2010339907 A1 AU 2010339907A1 AU 2010339907 A AU2010339907 A AU 2010339907A AU 2010339907 A AU2010339907 A AU 2010339907A AU 2010339907 A1 AU2010339907 A1 AU 2010339907A1
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
layer
exenatide
tablets
bioadhesive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2010339907A
Other languages
English (en)
Inventor
William W. Lee
Feng Lu
Yin Min
Liuying Shao
Hao SHE
Zhou Shen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NOD Pharmaceuticals Inc
Original Assignee
NOD Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN200910201248.3A external-priority patent/CN102100912B/zh
Priority claimed from CN201010227045.4A external-priority patent/CN102335431B/zh
Application filed by NOD Pharmaceuticals Inc filed Critical NOD Pharmaceuticals Inc
Publication of AU2010339907A1 publication Critical patent/AU2010339907A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2010339907A 2009-12-16 2010-12-16 Compositions and methods for oral drug delivery Abandoned AU2010339907A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US28714609P 2009-12-16 2009-12-16
CN200910201248.3 2009-12-16
CN200910201248.3A CN102100912B (zh) 2009-12-16 2009-12-16 一种给药组合物及其制备和使用方法
US61/287,146 2009-12-16
CN201010227045.4 2010-07-14
CN201010227045.4A CN102335431B (zh) 2010-07-14 2010-07-14 一种给药组合物及其制备和使用方法
US36591610P 2010-07-20 2010-07-20
US61/365,916 2010-07-20
PCT/US2010/060809 WO2011084618A2 (fr) 2009-12-16 2010-12-16 Compositions et procédés d'administration de médicaments par voie orale

Publications (1)

Publication Number Publication Date
AU2010339907A1 true AU2010339907A1 (en) 2012-07-05

Family

ID=44306059

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010339907A Abandoned AU2010339907A1 (en) 2009-12-16 2010-12-16 Compositions and methods for oral drug delivery

Country Status (5)

Country Link
EP (1) EP2512454A2 (fr)
JP (1) JP2013514976A (fr)
AU (1) AU2010339907A1 (fr)
CA (1) CA2784120A1 (fr)
WO (1) WO2011084618A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
PT2651398T (pt) 2010-12-16 2018-03-09 Novo Nordisk As Composições sólidas compreendendo um agonista de glp-1 e um sal de ácido n-(8-(2-hidroxibenzoil)amino) caprílico
EP2696687B1 (fr) 2011-04-12 2016-10-26 Novo Nordisk A/S Dérivés glp-1 double-acylatés
JP6157464B2 (ja) * 2011-07-19 2017-07-05 バクスアルタ ゲーエムベーハー 非抗凝固性硫酸化多糖の経口製剤を改善するための添加剤としての吸収促進剤
HUE062740T2 (hu) 2012-03-22 2023-12-28 Novo Nordisk As GLP-1 peptidek készítményei és elõállításuk
PT2827845T (pt) 2012-03-22 2019-03-29 Novo Nordisk As Composições compreendendo um agente de entrega e sua preparação
EP4331667A3 (fr) 2012-03-22 2024-05-08 Novo Nordisk A/S Compositions comprenant un agent d'administration et leur préparation
JP6517690B2 (ja) 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
US20160193154A1 (en) * 2013-07-24 2016-07-07 Novo Nordisk A/S Pharmaceutical Composition for Oral Insulin Administration Comprising a Tablet Core and an Anionic Copolymer Coating
KR101768446B1 (ko) 2014-03-21 2017-08-17 애니젠 주식회사 신규한 엑세나타이드 유사체 및 그의 용도
US11548940B2 (en) 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
CA3198322A1 (fr) 2014-05-15 2015-11-19 Rani Therapeutics, Llc Compositions pharmaceutiques et procedes de fabrication de masses solides comprenant des polypeptides et/ou des proteines
JP6737793B2 (ja) * 2015-01-29 2020-08-12 ノヴォ ノルディスク アー／エス 錠剤コアとポリビニルアルコールコーティングとを含む経口インスリン投与のための医薬組成物
JP7211704B2 (ja) * 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
US20180263915A1 (en) * 2015-01-29 2018-09-20 Novo Nordisk A/S Pharmaceutical Composition for Oral GLP-1 Administration Comprising a Tablet Core and Immediate Release Coating
PT3280447T (pt) * 2015-04-08 2019-05-14 Torrent Pharmaceuticals Ltd Formulações farmacêuticas
AU2016257813B2 (en) 2015-05-01 2021-05-13 Rani Therapeutics, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
CN104998251A (zh) * 2015-07-08 2015-10-28 哈尔滨吉象隆生物技术有限公司 用于口服肠溶制剂制备的具有促肠吸收作用的利拉鲁肽盐
CN105079793A (zh) * 2015-07-18 2015-11-25 哈尔滨吉象隆生物技术有限公司 一种可用于口服的利拉鲁肽与盐酸二甲双胍复方制剂
CN105079794A (zh) * 2015-07-18 2015-11-25 哈尔滨吉象隆生物技术有限公司 一种可用于口服的利拉鲁肽与磺脲类复方制剂
RU2617049C1 (ru) * 2016-05-12 2017-04-19 Федеральное государственное бюджетное учреждение "Национальный исследовательский центр "Курчатовский институт" Противоопухолевое лекарственное средство на основе никлозамида
BR112020014624A2 (pt) 2018-02-02 2020-12-08 Novo Nordisk A/S Composições sólidas compreendendo agonista de glp-1, sal de ácido n-(8-(2-hidroxibenzoil) amino)caprílico e lubrificante
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722941A (en) 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4525339A (en) 1982-10-15 1985-06-25 Hoffmann-La Roche Inc. Enteric coated oral dosage form
US4874795A (en) 1985-04-02 1989-10-17 Yesair David W Composition for delivery of orally administered drugs and other substances
DE3681754D1 (de) 1985-04-27 1991-11-07 Nitto Denko Corp Klebepflaster und arzneimittel fuer die mundhoehle.
NL8701143A (nl) 1986-05-27 1987-12-16 Sandoz Ag Farmaceutische preparaten.
US6156731A (en) 1989-05-10 2000-12-05 G. D. Searle & Co. Polypeptide composition for oral administration
JPH0813748B2 (ja) * 1990-04-23 1996-02-14 帝國製薬株式会社 大腸崩壊性ポリペプチド系経口製剤
JP3249147B2 (ja) 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
JPH064531B2 (ja) * 1990-06-04 1994-01-19 アイセロ化学株式会社 大腸崩壊性硬質カプセル
US5714167A (en) 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
CA2070061C (fr) 1991-06-07 2004-02-10 Shigeyuki Takama Composition pharmaceutique renfermant des polypeptides physiologiquement actives
US5318781A (en) 1993-04-06 1994-06-07 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
SE9302135D0 (sv) 1993-06-18 1993-06-18 Kabi Pharmacia Ab New pharmaceutical composition
US5424289A (en) 1993-07-30 1995-06-13 Alza Corporation Solid formulations of therapeutic proteins for gastrointestinal delivery
AU689250B2 (en) * 1994-04-22 1998-03-26 Astellas Pharma Inc. Colon-specific drug release system
KR100413202B1 (ko) 1994-11-17 2004-04-13 도레이 가부시끼가이샤 경피흡수제제
US5827534A (en) 1995-05-24 1998-10-27 University Of Maryland At Baltimore Oral dosage composition comprising zonnula occludens toxin and a therapeutic agent for intestinal delivery
US5817624A (en) 1995-06-05 1998-10-06 Alza Corporation Permeation enhancer compositions for increased absorption of therapeutic proteins through the colonic membrane
GB9516268D0 (en) 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
CA2184316A1 (fr) 1995-09-12 1997-03-13 Wei-Chi Liao Systeme d'administration buccale pour agents therapeutiques
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
CN1231592A (zh) 1996-10-30 1999-10-13 瑟垃技术有限公司 作为渗透促进剂的羟乙酸及其盐的脂肪酸酯
US5891474A (en) * 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
JP2002510319A (ja) 1997-07-01 2002-04-02 アイシス・ファーマシューティカルス・インコーポレーテッド オリゴヌクレオチドの消化管を介したデリバリーのための組成物及び方法
US6423334B1 (en) 1997-10-01 2002-07-23 Elan Corporation, Plc Composition and method for enhancing transport across gastrointestinal tract cell layers
JPH11246439A (ja) 1998-03-02 1999-09-14 Hisamitsu Pharmaceut Co Inc 経粘膜用吸収促進剤
JP4497725B2 (ja) 1998-11-27 2010-07-07 ▲高▼田 ▲寛▼治 消化管用薬物送達経口製剤
US6355270B1 (en) * 1999-01-11 2002-03-12 The Regents Of The University Of California Particles for oral delivery of peptides and proteins
US20070148228A1 (en) 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
ATE386508T1 (de) 1999-02-22 2008-03-15 Merrion Res I Ltd Feste orale dosierungsform enthaltend einen resorptionsverstärker
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US7316819B2 (en) 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
US20030124196A1 (en) 2001-08-22 2003-07-03 Susan Weinbach Pulsatile release compositions and methods for enhanced intestinal drug absorption
CN1816324A (zh) * 2003-07-04 2006-08-09 尼克麦德丹麦公司 口服用的含甲状旁腺激素(pth)的药物组合物
BRPI0507680A (pt) 2004-02-13 2007-07-17 Nod Pharmaceuticals Inc partìculas de fosfato de cálcio terapêuticas e métodos de fabricação e uso das mesmas
EP2626368B1 (fr) 2004-07-19 2016-12-21 Biocon Limited Conjugués insuline-oligomère, formulations et utilisations de ceux-ci
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US20090087484A1 (en) 2007-09-28 2009-04-02 Alza Corporation Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
US20090111736A1 (en) 2007-10-29 2009-04-30 Sri International Orally-Absorbed Solid Dose Formulation for Vancomycin
US20120128767A1 (en) 2008-05-01 2012-05-24 Lee William W Therapeutic calcium phosphate particles and methods of making and using same

Also Published As

Publication number Publication date
EP2512454A2 (fr) 2012-10-24
CA2784120A1 (fr) 2011-07-14
WO2011084618A2 (fr) 2011-07-14
WO2011084618A3 (fr) 2012-01-19
JP2013514976A (ja) 2013-05-02

Similar Documents

Publication Publication Date Title
US20110142889A1 (en) Compositions and methods for oral drug delivery
AU2010339907A1 (en) Compositions and methods for oral drug delivery
US20180098934A1 (en) Mucoadhesive devices for delivery of active agents
ES2301477T3 (es) Forma de dosificacion oral solida que contiene un potenciador.
EP0932396B1 (fr) Forme posologique pharmaceutique comportant plusieurs enrobages polymeres enteriques, destinee a agir dans le colon
US8828431B2 (en) Solid oral dosage form containing an enhancer
AU2018387769B2 (en) Oral delivery of active drug substances
CA2642479C (fr) Systeme de gastro-retention pour de livrer des macromolecules
EP2526950A1 (fr) Forme pharmaceutique solide par voie orale contenant un activateur
CN102552919B (zh) 一种给药组合物及其制备和使用方法
CN102100912B (zh) 一种给药组合物及其制备和使用方法
WO2009125432A2 (fr) Systèmes d'administration de médicament expansible alimentés par gaz
CN102335431B (zh) 一种给药组合物及其制备和使用方法
WO2015026552A2 (fr) Dispositifs mucoadhésifs permettant l'administration d'agents actifs
CN110974943A (zh) 一种口服胰岛素药物制剂及其制备方法
US20190192442A1 (en) Room temperature stable oral calcitonin formulation
WO2023131885A1 (fr) Dispositif d'administration de médicament auto-expansible à avaler et ses utilisations
WO2023166224A1 (fr) Formulations gastro-rétentives contenant une protéine ou un peptide
CN110809464A (zh) 粘膜附着性口服制剂

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application